US Patent Office allows further Patent for RESP3000

Respiratorius announces that the US Patent Office issued a Notice of Allowance for a patent application for RESP3000 series, designed for use in cardiovascular diagnostics with PET-camera. The granted patent includes requirements for enhanced product protection and is in force until December 2031.

The substances in the RESP3000 series specifically binds to mitochondria, and since the heart muscle is rich in mitochondria allowing for high contrast and detailed PET images, which is also confirmed in the completed "proof of concept" study.

Markers for PET-cameras today attracts interest from a diagnostic perspective, since the images results in excellent resolution while the radiation dose can be kept low. This has contributed to a market in strong growth, with an estimated size of $ 4 billion in 2018, and thereby a high level of activity in the industry.

"A new patent approval in the US further strengthens patent protection for RESP3000 on the single most important market, says CEO Johan Drott in a comment".

This information is information which Respiratorius AB (publ) is obliged to publish under the EU Market Abuse Regulation. The information was provided by the above contact person's auspices, for publication on 28 March 2017

Johan Drott

CEO Respiratorius AB

+46 709-22 41 40

johan.drott@respiratorius.com

Respiratorius AB (publ) is developing drug candidates with the goal to launch drugs for common diseases cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. In addition, the project portfolio is a project for improved diagnosis of certain cardiovascular diseases.

Tags:

Subscribe

Documents & Links

Quotes

A new patent approval in the US further strengthens patent protection for RESP3000 on the single most important market
CEO Johan Drott